Price to Book Value Chart

View Price to Book Value for VYGR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Price to Book Value Chart
Start Trial

Historical Price to Book Value Data

View and export this data back to 2015. Start Trial.
Date Value
August 31, 2026 1.369
August 28, 2026 1.405
August 27, 2026 1.373
August 26, 2026 1.373
August 25, 2026 1.381
August 24, 2026 1.365
August 21, 2026 1.346
August 20, 2026 1.318
August 19, 2026 1.354
August 18, 2026 1.310
August 17, 2026 1.282
August 14, 2026 1.298
August 13, 2026 1.278
August 12, 2026 1.270
August 11, 2026 1.270
August 10, 2026 1.258
August 07, 2026 1.298
August 06, 2026 1.242
August 05, 2026 1.230
August 04, 2026 1.240
August 03, 2026 1.191
July 31, 2026 1.203
July 30, 2026 1.242
July 29, 2026 1.191
July 28, 2026 1.207
Date Value
July 27, 2026 1.226
July 24, 2026 1.230
July 23, 2026 1.226
July 22, 2026 1.230
July 21, 2026 1.246
July 20, 2026 1.211
July 17, 2026 1.258
July 16, 2026 1.207
July 15, 2026 1.270
July 14, 2026 1.254
July 13, 2026 1.286
July 10, 2026 1.365
July 09, 2026 1.461
July 08, 2026 1.480
July 07, 2026 1.500
July 06, 2026 1.437
July 02, 2026 1.500
July 01, 2026 1.429
June 30, 2026 1.389
June 29, 2026 1.243
June 26, 2026 1.247
June 25, 2026 1.233
June 24, 2026 1.278
June 23, 2026 1.285
June 22, 2026 1.292

Price to Book Ratio Definition

Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.

Read full definition.

Price to Book Value Range, Past 5 Years

View Price to Book Value Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Price to Book Value Benchmarks

View Price to Book Value Benchmarks
Start Trial
Agenus, Inc. --
Amgen, Inc. 20.26
Anika Therapeutics, Inc. 2.066
BioCryst Pharmaceuticals, Inc. --
Imunon, Inc. 1.764

Price to Book Value Related Metrics

PS Ratio 5.900
Price 3.42
Earnings Yield -53.02%
Market Cap 209.55M